TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

NeoGenomics, Inc. (NASDAQ:NEO) Investor Investigation Over Potential Wrongdoing Announced

  • Investors who purchased shares of NeoGenomics, Inc. (NASDAQ:NEO) have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
NeoGenomics, Inc
Security
NASDAQ: NEO

Summary

An investigation on behalf of investors in shares of NeoGenomics, Inc. (NASDAQ:NEO) was announced over potential breaches of fiduciary duties by certain officers and directors at NeoGenomics, Inc.

The investigation by a law firm concerns whether certain NeoGenomics, Inc. (NASDAQ:NEO officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Fort Myers, FL based NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. NeoGenomics, Inc. reported that its annual Total Revenue rose from $244.08 million in 2016 to $258.61 million in 2017 and that its Net Loss declined from $5.72 million in 2016 to $0.85 million in 2017.

Shares of NeoGenomics, Inc. (NASDAQ:NEO) increased from $3.88 per share in January 2015 to as high as $11.13 per share in September 2017.

On March 9, 2017, NASDAQ:NEO shares closed at $8.71 per share.

Start Monitoring Your Investments